Cyclo Therapeutics Announces Last Patient Last Visit in Phase 1/2 Trial Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C
Topline results from Phase 1/2 study on track for March 2021Individual and cumulative data seen to-date show Trappsol® Cyclo™ to be well tolerated with a favorable safety profile for all dose groups and to have encouraging signals in efficacyPivotal Phase 3...
Cyclo Therapeutics Appoints Gerald F. Cox, MD, PhD as Acting Chief Medical Officer
- Seasoned biotechnology executive with 20-year successful track record of drug development for rare genetic diseases and extensive worldwide regulatory experience - Internationally renowned for clinical development of innovative drugs with broad experience in small...
Cyclo Therapeutics Unveils New Corporate Identity and Reaffirms Commitment to Improving Quality of Life and Providing Hope for Patients and Families
- The evolution of the Company's brand identity aligns with Cyclo Therapeutics' science-based, patient-focus approach to drug development- Company developing cyclodextrin-based products for the treatment of diseases with significant unmet needs, including Niemann-Pick...
Cyclo Therapeutics Presents Positive Data from Clinical Development Program for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2021
Data from ongoing Phase 1 extension study shows improvement in disease features or disease stabilization with home-based intravenous infusions of Trappsol® Cyclo™Phase 1 biomarker 24S-hydroxycholesterol demonstrates clearance of excess cholesterol from the...
Cyclo Therapeutics to Present on Its Clinical and Drug Development Program for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2021
GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company developing a cyclodextrin platform for the treatment of Neurodegenerative Diseases, including their lead candidate...
Cyclo Therapeutics Announces Positive Efficacy Data from Extension Protocol with Trappsol® Cyclo™ in Patients with Niemann-Pick Disease Type C
Home-based intravenous infusions of Trappsol® Cyclo™ for up to one year show improvement in disease features or disease stabilizationGAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) (NasdaqCM:CYTHW), a clinical stage biotechnology company...
Cyclo Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares of Common Stock in Connection with its Underwritten Public Offering
GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. ("Cyclo Therapeutics" or the "Company") (NasdaqCM:CYTH) (NasdaqCM:CYTHW), a clinical stage biotechnology company developing a cyclodextrin platform for the treatment of Neurodegenerative Diseases, including their lead...
Cyclo Therapeutics Announces Pricing of $12.5 Million Public Offering
Transaction Includes Uplisting to Nasdaq and Reverse Stock SplitGAINESVILLE, Fla. - Cyclo Therapeutics, Inc. ("Cyclo Therapeutics" or the "Company") (NasdaqCM: CYTH) (NasdaqCM:CYTHW), a clinical stage biotechnology company developing a cyclodextrin platform for the...